FDA Ends Penalties on Compounded Peptides BPC-157, TB-500 and Four Others

The U.S. government will no longer penalize American companies for producing six popular peptides, including BPC-157 and TB-500, which are widely used in wellness and recovery products. This decision removes regulatory action against compounding pharmacies that manufacture these substances, marking a significant shift in enforcement policy. The move affects a growing market of consumers seeking alternative therapies for healing, inflammation, and performance. By easing restrictions, federal regulators are acknowledging demand for these compounds while leaving questions about long-term safety and oversight. Compounding pharmacies can now produce these peptides without fear of federal penalties, though state regulations may still apply. This change could expand access and lower costs for users, but it also raises concerns about quality control and medical guidance. The decision is likely to fuel further growth in the peptide industry as more companies enter the space. For consumers, the key takeaway is that availability may increase, but professional medical advice remains essential.